Wikisage, the free encyclopedia of the second generation, is digital heritage
Rufinamide: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
(→ATC) |
||
| Line 16: | Line 16: | ||
https://www.whocc.no/atc_ddd_index/?code=N03AF03 | https://www.whocc.no/atc_ddd_index/?code=N03AF03 | ||
{{refs}} | |||
{{Wikidata|Q408565}} | {{Wikidata|Q408565}} | ||
[[Category:Anticonvulsants]] | [[Category:Anticonvulsants]] | ||
Revision as of 15:20, 21 May 2019
Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconclusive. Otsuka et al. (2014) state rufinamide as an efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2]
"Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]
It is an inductor of CYP 450
Weblinks
ATC
https://www.whocc.no/atc_ddd_index/?code=N03AF03
